A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes

Overview

The purpose of this study is to determine treatment effects in patients with retinal pigment epithelium detachment (PED) in relation to Age Related Maculopathy (AMD). Patients with newly diagnosed PED without choroidal neovascularisations (CNV), will be randomized to either treatment or observation. The treatment group will first be given injections with anti Vascular Endothelium Growth Factor (anti-VEGF). If the injections do not have any effect, Verteporfin Photodynamic Therapy (PDT) will be given. All patients will be followed for a period of 2 years. It is hypothesized that treatment stops the progression of the disease and stabilizes the vision in this subgroup of patients with AMD.

Full Title of Study: “Pigment Epithelium Detachment – a Prospective Clinical Study. PED-study.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2015

Interventions

  • Drug: Aflibercept
    • 2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.
  • Drug: Verteporfin
    • given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.

Arms, Groups and Cohorts

  • Experimental: Treatment
    • aflibercept intravitreal injections, 2.0 mg monthly x 3 doses, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; aflibercept intravitreal injections, 2.0 mg x 3 doses is repeated, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; verteporfin photo dynamic therapy.
  • No Intervention: Observation

Clinical Trial Outcome Measures

Primary Measures

  • Mean change in visual acuity from baseline to 24 months
    • Time Frame: 24 months
    • Best corrected visual acuity (BCVA) on the Early Treatment for Diabetic Retinopathy Study (ETDRS) chart at 4 meters will be compared

Secondary Measures

  • Visual acuity from baseline to 6 months
    • Time Frame: 6 months
    • BCVA on ETDRS will be compared from baseline to 6 months
  • Visual acuity from baseline to 12 months
    • Time Frame: 12 months
    • BCVA on ETDRS will be compared from baseline to 12 months
  • Safety
    • Time Frame: 24 months
    • Incidence and severity of ocular and non-ocular adverse events will be evaluated through 24 months
  • Change in Optical Coherence Tomography (OCT) measurements from baseline through 24 months
    • Time Frame: 24 months
    • Change in OCT Central Retinal Thickness (CRT) and Volume of PED from baseline through 24 months
  • Development of choroidal neovascularisations (CNV)
    • Time Frame: 24 months
    • Development of CNV seen with OCT, fluorescein and indocyanine green imaging

Participating in This Clinical Trial

Inclusion Criteria

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age > 50 years
  • Pigment epithelium detachment in an eye not earlier treated with anti-VEGF or verteporfin PDT.
  • ETDRS Best Corrected Visual acuity 20/32 – 20/400

Exclusion Criteria

  • Prior treatment with verteporfin, or external-beam radiation therapy, or transpupillary thermotherapy, Previous subfoveal focal laser photocoagulation involving the foveal center, History of vitrectomy, submacular surgery, or other surgical intervention for AMD.
  • CNV, Subfoveal fibrosis or atrophy in study eye.
  • Concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy, advanced glaucoma) or require medical or surgical intervention during the study. Active intraocular inflammation in the study eye.

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Norwegian University of Science and Technology
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Tor Elsaas, Prof. MD, Principal Investigator, Norwegian University of Science and Technology

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.